Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 4/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25836269 | 0.93 | FABP7 (0.47) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL12415464 | 0.79 | FABP7 (0.52) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL8694818 | 0.77 | FABP7 (0.50) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL8694813 | 0.77 | FABP7 (0.50) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL8694810 | 0.77 | FABP7 (0.50) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL6800695 | 0.76 | FABP7 (0.56) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL32677645 | 0.76 | FABP7 (0.59) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL8498305 | 0.76 | FABP7 (0.59) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL8498310 | 0.76 | FABP7 (0.59) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL7757018 | 0.75 | FABP7 (0.73) | FABP7FABP5ALDH1A1HCAR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702632-B2 | Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease | UNIVERSITY OF MASSACHUSETTS (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702632-B2 | Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease | ICOS, CD4, NFATC1 | FABP7 3299/4885FABP5 1372/4885ALDH1A1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.